#USA #Wayne #CluePoints #Risk-Based Quality Management #Clinical Data Review

CluePoints Earns Fierce Life Sciences Innovation Awards Finalist Status

In an exciting announcement, CluePoints has secured its place as a finalist in the Data Analytics/Business Intelligence category at the prestigious 2026 Fierce Life Sciences Innovation Awards. This recognition is a testament to CluePoints' continued advancements in Risk-Based Quality Management (RBQM) and clinical data quality oversight software, further reinforcing its status as a leader in the life sciences sector.

Innovative Approach to Clinical Data Review

CluePoints has garnered attention for its fresh approach to clinical data review. The company has made significant enhancements to its RBQM software, integrating three new capabilities: Intelligent Query Detection (IQD), Medical and Safety Review (MSR), and Intelligent Medical Coding (IMC). These capabilities not only extend its existing statistical engine but also unify previously fragmented data review methodologies into a cohesive model.

The CluePoints platform has actively contributed to derisking numerous studies, successfully identifying over 250,000 potential issues in clinical data. The integration of IQD, MSR, and IMC ensures that vital patient safety signals are analyzed systematically, rather than in isolation. This innovative approach highlights CluePoints' commitment to improving data compliance and enhancing patient safety across clinical trials.

A Unique Perspective on AI in Data Management

Moreover, while many companies rush to incorporate AI into their operations, CluePoints has adopted a more strategic approach. Rather than merely adding AI to existing workflows, CluePoints enhances its statistical models with AI only where it truly improves the outcomes. Every output generated by the platform is designed to be explainable, auditable, and defensible.

Chief Commercial Officer Martin Magazzolo emphasized, "The challenge in clinical trials has never been the availability of data; rather, it has been the fragmented tools and disconnected systems that hinder timely action on valuable data insights. CluePoints’ model allows clinical teams to detect issues earlier and address them more effectively, ensuring they are audit-ready with confidence. We're thrilled that our dedication to transforming raw data into actionable intelligence is being acknowledged at this year's Fierce awards."

Looking Forward to the Awards Gala

The winners of the Fierce Life Sciences Innovation Awards will be unveiled at the Fierce Vanguard Awards Gala on November 19, 2026, at The Lighthouse at Pier 61 in New York City. This event promises to be a highlight for innovators in the life sciences industry.

By positioning themselves at the intersection of advanced statistics and machine learning, CluePoints continues to support consistent and sound decision-making across a broad spectrum of clinical trials. Their innovative solutions with a focus on maintaining traceable, inspection-ready oversight throughout the study lifecycle make them a crucial partner for pharmaceutical, biotechnology, and contract research organizations.

To find out more about how CluePoints is reshaping clinical data management, visit CluePoints.com.